All abstracts are blinded, peer-reviewed and ranked on the basis of scientific merit by experts in the category selected. The AASLD Scientific Program Committee uses these rankings to develop the scientific program of the conference. Abstracts are allocated to short oral plenary and parallel presentations (10 minute presentation plus a 5 minute Q&A period) and poster sessions based on their focus of interest. Authors who do not wish to be considered for oral presentation should check the "Poster Only" option under Step 2: Properties in the online abstract submitter (Opens April 1 and closes June 1). All abstract presenters must register for the AASLD Annual Meeting.
Abstracts are scored by at least four reviewers for each category and ranked according to numerical score. Reviewers are blinded to the author's names and affiliations. Reviewers with conflicts do not score pertinent abstracts. Abstracts are ranked within the category that is selected by the submitter, although if selected, abstracts may be moved into other content areas for presentation.
Abstracts are selected for oral and poster presentations based on the integration of the abstract subject into sessions within a specific topic, abstract rank, and suitability of the content for presentation. Posters of Distinction are considered to be particularly noteworthy and represent the top 10% of all accepted poster presentations.
If abstracts contain incomplete data at the time of submission, the abstract will receive a lower priority score. In such circumstances, consideration should be given to submitting the complete data as a "late-breaker" for the Annual Meeting.
Original research that was not completed until after the June 1, 2018 abstract deadline for The Liver Meeting® may be eligible for submission as a late-breaking abstract. The late-breaking abstract submission period will open in September 2018.
Novel clinical observations can provide new insight into clinical phenotypes or pathogenesis of disease. Case reports are not frequently submitted to The Liver Meeting® but authors who so choose may submit one using the same guidelines outlined below for standard abstract submission. Case reports will be scored and ranked by the same review team that scores abstract submissions for the category and descriptor selected by the submitting author.
The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals.
It is the policy of the American Association for the Study of Liver Diseases (AASLD) to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD sponsored programs, as well as planners and committee members are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.
All abstract authors must complete their own financial disclosure statement on the abstract submission site either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT have the ability to submit disclosures on behalf of a co-author.
Disclosures not received before the deadline stated in the abstract acceptance notice will be administratively withdrawn.
Accepted abstracts are made available to the public on the AASLD website in early October, and are published in the October supplement of HEPATOLOGY. Late-breaking abstracts are available to the public on the AASLD website in early November, and are published in the December issue of HEPATOLOGY. Information contained in those abstracts may not be released until the abstracts appear on the AASLD website. Academic institutions, private organizations, and companies with products whose values may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract on the AASLD website. However, information beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional or new information that will be available at the time of the meeting is embargoed from release to the general public until the first day of the meeting.
Information released prior to this day is a violation of the AASLD Abstract Embargo Policy and the abstract is subject to withdrawal from The Liver Meeting® program. Authors are responsible for notifying financial and other sponsors about this policy.
AASLD may allow for exceptions, on a case-by-case basis, to the Abstract Embargo Policy for compelled disclosures mandated by federal securities laws. However, AASLD requires the company President, General Counsel, or other appropriate official of a company seeking such an exception to attest in writing to the specific facts in support of the request, including exactly how the securities laws are implicated, with statutory citation(s). General statements of the need to comply with the law will not be considered sufficient. Requests for an exception must be sent to AASLD. AASLD requires a minimum of five ( 5 ) days from receipt of the request to evaluate the request. In granting an exception, AASLD requires the company to state in their public disclosure that the complete and final results will be presented at The Liver Meeting®. AASLD will also require the inclusion of unreleased and unique data in such a presentation at The Liver Meeting®.
Public release of a journal article relevant to the abstract will be considered an exception to the Embargo Policy if at the time of the abstract submission deadline, the decision concerning the manuscript had not been revealed to the authors.